Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO 2017 Wrap-Up Podcast

Executive Summary

Analysts from Informa Pharma Intelligence's Biomedtracker, Datamonitor Healthcare and Citeline discuss their impressions following the 2017 annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago from June 2-6, 2017.

In this audio-only podcast, analysts from Informa Pharma Intelligence discuss key impressions from the 2017 annual meeting of the American Society of Clinical Oncology (ASCO). Join Robert Jeng (Biomedtracker), Dominique Fontanilla (Datamonitor Healthcare) and Maria Berezina (Citeline, Trialtrove) as they discuss topics including:

  • Anti-BCMA CAR-T therapies
  • LAG3 and GITR checkpoints
  • TRK inhibitor larotrectinib (LOXO-101)
  • Major plenary talks and drug value
  • Tumor agnostic drug approvals

Advertisement

Related Content

Value & Pricing Perspectives From ASCO, In Brief
Bluebird Flies On 100% Response Rate For Anti-BCMA CAR-T
Loxo's Larotrectinib Requires Paradigm-Change In Clinical Practice

Topics

Advertisement
UsernamePublicRestriction

Register

SC098922

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel